Phage Display Platform

Tek Biotech is committed to providing customers with high-affinity and high-specificity antibody drug discovery services, which will provide strong support for customers' subsequent downstream research and development work, such as CAR-T/CAR-NK lead sequence design, antibody humanization, drug target antibody development, antibody coupled drug (ADC) development, bispecific antibody development, and highly efficient blocking neutralizing antibody development. With 10 years of experience in drug antibody discovery, Tek Biotech is able to provide high-quality camel-derived VHH nanoantibody discovery services for targets including but not limited to proteins, peptides, small molecules, viruses, membrane proteins, and mRNAs, as well as discovery of scFv from different species (rabbit, mouse, sheep, camel, etc.).

Phage display technology（Phagepro Tech^®） is a biotechnology that inserts DNA sequences of exogenous proteins or polypeptides into the appropriate positions of thestructural genes of phage shell proteins, usually the P3 protein of M13 phage, so that the exogenous genes can be displayed on the surface of phage along with the expression of shell proteins. Based on Phage display technology（Phagepro Tech^®）, Tek Biotech is able to provide high-quality phage display services for single-chain antibodies, including but not limited to VHH, scFv, etc., with phage library capacity of up to 10^8-10^9, and library diversity, insertion rate, and positivity rate of up to 90% or more, which can satisfy all kinds of customers' requirements for the quality of antibody phage display libraries. The advantages of phage display are The advantage of phage display lies in the diversity of mutant antibody genes in nanobody libraries, with each recombinant phage (commonly used phage is M13 phage) displaying different antigen-binding domains on its surface. Compared with the traditional hybridoma method, phage display technology has a very outstanding efficiency advantage in the display and screening of antibody genes (e.g., the fusion efficiency of hybridomas is generally<0.4%, i.e., out of 1000 fused cells, approximately 4 out of 5 fused cells will be identified). In 1000 times of fusion, there are about 4 fusions; while phage display technology can easily obtain 10^8-10^9 correct antibody sequences). Meanwhile, Teckbio can also provide one-stop technical services for antibody phage display supporting downstream antibody in vitro validation (including but not limited to affinity validation, antibody blocking validation, cross-reactivity validation, and other downstream validation experiments), antibody humanization, antibody affinity maturation, CAR-T/CAR-NK pilot sequence design, and cell-killing validation, etc. The customer only needs to provide the specific experimental needs and Customers only need to provide specific experimental requirements and target information, and Tek Biotech's scientists will be able to design and personalize the solutions according to the needs of the customers, which will help the customers' scientific research projects and drug antibody development.

█ Phage Display Antibody Library Construction Service

Tek Biotech can provide customers with camel-derived VHH nanobody libraries, scFv antibody libraries and other library construction and screening services. The VHH nanobody library, also known as camel-derived heavy chain antibody library, has a molecular weight of 15kDa and is a unique antibody produced by camel-derived animals. The camel-derived VHH antibody (also known as nanobody) phage display discovery pathway, which is currently widely used in CAR-T/CAR-NK therapeutic, is shown in Figure 1:

Figure 1 Camel derived VHH antibody discovery service based on phage technology platform

█ Content and Periodocity of Services

█ Service Advantages

-- Wide range of species: human, mouse, rabbit, sheep, alpaca, llama, fish and other species are compatible for monoclonal antibody development (not applicable to bovine monoclonal antibody development).

-- A variety of camel-derived immunizations are available, including but not limited to llama, alpaca, and llama, etc., and the animal source background is clear.

-- Immunization bases: sufficient animal resources, including but not limited to camel, mouse, rabbit and sheep.

-- Short development cycle: 4-6 weeks from PBMC acquisition, library construction to antibody sequence screening.

-- A variety of antibody libraries for phage display: VHH antibody library display, scFv antibody library display, etc.

-- Various target antibody discovery services: protein, peptide, small molecule, virus, membrane protein, mRNA, etc. (we can design customized immunization programs with multiple types of antigens for specific project requirements)

-- Mature technology platform: library capacity up to 10^8-10^9, insertion rate >90%, and the affinity of antibodies obtained from screening is generally at nM- pM level.

-- High standard of delivery: potency guarantee, library quality assurance, high affinity and high specificity antibody guarantee, providing strong support for customers' downstream experiments.

-- Traceability of experimental records: QC standards (immuno potency, PBMC QC, library QC and screening validation QC), Chinese and English lab reports, original lab records.

-- One-to-one customized solutions (including immunization, library construction, screening and subsequent in vitro expression validation) to meet the needs of various customers' research projects.

-- Variety of library screening methods: design the best screening method according to customer's project requirements, such as solid phase screening, liquid phase screening, cell screening, magnetic bead screening, etc.

-- We can provide a series of complementary downstream drug antibody development services, including in vitro antibody expression validation, antibody humanization, antibody affinity maturation, bispecific antibody development, CAR-T lead sequence molecule design, and antibody coupled drug (ADC) development.